Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at so that we can update the bibliography.


 (PDF, 5MB, 226 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website



Export 31 results:
Author Title Type [ Year(Desc)]
Filters: Author is Souverein, P. C.  [Clear All Filters]
S. H. Mahmoudpour, Baranova, E. V., Souverein, P. C., Asselbergs, F. W., de Boer, A., and van der Zee, A. H. Maitlan, Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink, Br J Clin Pharmacol, vol. 82, pp. 1647-1659, 2016.
C. Huerta, Abbing-Karahagopian, V., Requena, G., Oliva, B., Alvarez, Y., Gardarsdottir, H., Miret, M., Schneider, C., Gil, M., Souverein, P. C., De Bruin, M. L., Slattery, J., de Groot, M. C., Hesse, U., Rottenkolber, M., Schmiedl, S., Montero, D., Bate, A., Ruigomez, A., Garcia-Rodriguez, L. A., Johansson, S., de Vries, F., Schlienger, R. G., Reynolds, R. F., Klungel, O. H., and de Abajo, F. J., Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project, Pharmacoepidemiol Drug Saf, vol. 25 Suppl 1, pp. 56-65, 2016.
B. P. Verhaegh, de Vries, F., Masclee, A. A., Keshavarzian, A., de Boer, A., Souverein, P. C., Pierik, M. J., and Jonkers, D. M., High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors, Aliment Pharmacol Ther, vol. 43, pp. 1004-13, 2016.
G. Requena, Huerta, C., Gardarsdottir, H., Logie, J., Gonzalez-Gonzalez, R., Abbing-Karahagopian, V., Miret, M., Schneider, C., Souverein, P. C., Webb, D., Afonso, A., Boudiaf, N., Martin, E., Oliva, B., Alvarez, A., de Groot, M. C., Bate, A., Johansson, S., Schlienger, R., Reynolds, R., Klungel, O. H., and de Abajo, F. J., Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project, Pharmacoepidemiol Drug Saf, vol. 25 Suppl 1, pp. 66-78, 2016.
A. G. Boef, Souverein, P. C., Vandenbroucke, J. P., A. Vlieg, vanHylckama, de Boer, A., le Cessie, S., and Dekkers, O. M., Instrumental variable analysis as a complementary analysis in studies of adverse effects: venous thromboembolism and second-generation versus third-generation oral contraceptives, Pharmacoepidemiol Drug Saf, vol. 25, pp. 317-24, 2016.
R. F. Gulluoglu, Souverein, P. C., van den Ham, H. A., de Boer, A., and Komen, J., Comparative effectiveness and safety of direct oral anticoagulants versus warfarin in UK patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study, Pharmacoepidemiol Drug Saf, 2020.
S. Abtahi, Driessen, J. H. M., Burden, A. M., Souverein, P. C., van den Bergh, J. P., van Staa, T. P., Boonen, A., and de Vries, F., Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study, Ann Rheum Dis, 2020.
Y. Zhang, Souverein, P. C., Gardarsdottir, H., van den Ham, H. A., van der Zee, A. H. Maitlan, and de Boer, A., Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study, Br J Clin Pharmacol, 2020.
I. J. A. de Bruin, Wyers, C. E., Souverein, P. C., van Staa, T. P., Geusens, P., van den Bergh, J. P. W., de Vries, F., and Driessen, J. H. M., The risk of new fragility fractures in patients with chronic kidney disease and hip fracture-a population-based cohort study in the UK, Osteoporos Int, 2020.
T. A. Althunian, de Boer, A., Groenwold, R. H. H., Rengerink, K. O., Souverein, P. C., and Klungel, O. H., Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study, Pharmacoepidemiol Drug Saf, 2020.
[Page last reviewed 6 April 2021]